Form 4: Vor Biopharma Director Daniella Beckman Granted 30,000 Stock Options

Vor Biopharma Inc. director Daniella Beckman was granted 30,000 stock options with an exercise price of $0.1868 per share, vesting over approximately one year.

Summary

• Daniella Beckman, a Director at Vor Biopharma Inc. (VOR), was granted 30,000 stock options.
• The options have an exercise price of $0.1868 per share.
• The transaction date for this grant was May 22, 2025.
• The options were granted under the Issuer's non-employee director compensation policy.
• The shares underlying the option will vest and become exercisable on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Beckman's continued service as a director through the vesting date.
• The options have an expiration date of May 21, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options to a director is a routine compensation event that aligns interests, but it doesn't indicate significant operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $0.1868 is relatively low, potentially offering significant upside if the company's stock price appreciates.

Negatives

• The grant of new options could lead to minor dilution for existing shareholders if exercised, though the amount is relatively small in the context of a public company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

This filing is a standard disclosure of director compensation in the biopharmaceutical industry, reflecting common practices of using equity grants to incentivize and retain key personnel. It does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Daniella Beckman, a director of Vor Biopharma Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance.
• Director (Daniella Beckman): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders following the grant date, subject to continued service.

Key Dates

Keywords

Vor Biopharma, VOR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biopharma, Compensation Policy